These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25343079)

  • 1. New opportunity for orphan drug development in Japan: Early exploratory clinical trial bases promote drug translation from basic studies to clinical application.
    Song P; Gao J; Kokudo N; Tang W
    Intractable Rare Dis Res; 2012 May; 1(2):95-7. PubMed ID: 25343079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intractable and rare diseases research in Asia.
    Song P; Gao J; Inagaki Y; Kokudo N; Tang W
    Biosci Trends; 2012 Apr; 6(2):48-51. PubMed ID: 22621985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.
    Song P; Gao J; Inagaki Y; Kokudo N; Tang W
    Intractable Rare Dis Res; 2012 Feb; 1(1):3-9. PubMed ID: 25343064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
    Murakami M; Narukawa M
    Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orphan drugs: the regulatory environment.
    Franco P
    Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks.
    Tsukamoto K; Carroll KA; Onishi T; Matsumaru N; Brasseur D; Nakamura H
    Clin Ther; 2016 Mar; 38(3):574-81. PubMed ID: 26869192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The availability and affordability of orphan drugs for rare diseases in China.
    Gong S; Wang Y; Pan X; Zhang L; Huang R; Chen X; Hu J; Xu Y; Jin S
    Orphanet J Rare Dis; 2016 Feb; 11():20. PubMed ID: 26920579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Orphan drugs].
    Kolár J; Chalabala M; Srámková H
    Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Global strategy for rare and intractable diseases].
    Kawashima Kodama T
    Rinsho Shinkeigaku; 2013; 23(11):1283-6. PubMed ID: 24291960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America.
    Arnold RJ; Bighash L; Bryón Nieto A; Tannus Branco de Araújo G; Gay-Molina JG; Augustovski F
    F1000Res; 2015; 4():57. PubMed ID: 25844162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
    Hirota S; Yamaguchi T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.
    Maeda K; Kaneko M; Narukawa M; Arato T
    Orphanet J Rare Dis; 2017 Aug; 12(1):143. PubMed ID: 28835285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.